Nicox S A : to Present at the H.C. Wainwright Virtual BioConnect Conference

FOR INFORMATION

Nicox to Present at the H.C. Wainwright Virtual BioConnect Conference

January 7, 2021

Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present in a fireside chat at the H.C. Wainwright BioConnect Conference being held virtually on January 11-14, 2021.

A video webcast of Nicox's presentation will be available on-demand from Monday January 11 at 6:00 a.m. EST for one week by clicking hereand accessible on Nicox's website (www.nicox.com) in the "Presentations & Events" section. The video webcast will be available for 90 days.

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Victor Floc'h	Paris, France
Cantor Fitzgerald	Louise Chen	New York, U.S.
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Damien Choplain	Paris, France
Oppenheimer & Co	Hartaj Singh	New York, U.S.

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer

Executive Vice President, Chief Business Officer

& Head of Corporate Development

T [phone]

Investors & Media	Media
United States & Europe	France
LifeSci Advisors, LLC	LifeSci Advisors, LLC
Mary-Ann Chang	Sophie Baumont
T [phone]	M [phone]
[e-mail]	[e-mail]
www.nicox.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox's website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox's website..

Nicox S.A.

Drakkar 2

Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France

T [phone] F [phone]

www.nicox.com